参考文献/References:
[1]Jhaveri K,Esteva FJ.Pertuzumab in the Treatment of HER2+ Breast Cancer[J].J Natl Compr Canc Netw,2014,12(4):591-599.
[2]刘现义,李中,王晓春,等.人乳头状瘤病毒感染与乳腺癌的关系及P16蛋白表达的相关性[J].中华医院感染学杂志,2016,26(9):2120-2122.
[3]Wang J,Mao X,Zhang Y,et al.Genome-wide screening of CpG island methylation changes induced by low-does X-ray radiation in mice[J].J Southern Med Univ,2014,34(2):228-236.
[4]Wang L,Zhan X,Shen X,et al.P16 promotes the growth and mobility potential of breast cancer both in vitro and in vivo:the key role of the activation of IL-6/JAK2/STAT3 signaling[J].Mol Cell Biochem,2018,446(2):137-148.
[5]张一兵,胡继卫,卢鹤翔,等.EZH2、p16启动子在乳腺癌亚型中的表达及其与临床病理特征的关系[J].中国现代医学杂志,2018,28(21):42-47.
[6]Kobierzycki C,Grzegrzolka J,Glatzel-Plucinska N,et al.Expression of p16 and SATB1 in Invasive Ductal Breast Cancer - A Preliminary Study[J].In Vivo,2018,32(4):731-736.
[7]Cappellani A,Di Vita M,Zanghi A,et al.Prognostic factors in elderly patients with breast cancer[J].BMC Surg,2013,9(2):225-231.
[8]张顺礼,胡继卫,马杰,等.不同亚型乳腺癌组织中p16基因甲基化与蛋白表达及临床病理特征的关系[J].实用临床医药杂志,2016,20(11):47-49,58.
[9]Choi EJ,Yun JA,Jeon EK,et al.Prognostic significance of RSPO1,WNT1,and SDC1 expression in invasive ductal carcinoma of the breast[J].World J Surg Oncol,2013,11(4):314-321.
[10]徐锦屏,沈卫达,周英姿,等.p16、p27蛋白与乳腺癌临床病理特征的关系及预后价值[J].肿瘤研究与临床,2016,28(5):315-317.
[11]Dalley AJ,Pitty LP,Major AG,et al.Expression of ABCG2 and Bmi-1 in oral potentially malignant lesions and oral squamous cell carcinoma[J].Cancer Med,2017,3(2):273-279.
[12]杨军,黄小钟,郭睿,等.p16 INK4a蛋白可作为乳腺癌特异性分子标志[J].南方医科大学学报,2016,36(6):751-755.
[13]Kozomara Z,Supic G,Krivokuca A,et al.Promoter hypermethylation of p16, BRCA1 and RASSF1A genes in triple-negative breast cancer patients from Serbia[J].J BUON,2018,23(3):684-691.